NTII Neurobiological Technologies (MM)

Scimitar Equity Research Issues Review of Neurobiological Technologies, Inc. BOSTON, Nov. 9 /PRNewswire/ -- Scimitar Equity Research, Inc. (Scimitar) issues a review of Neurobiological Technologies, Inc. (NASDAQ:NTII), entitled, "The Engines of Share Price Growth: A Pipeline of Three Late Stage Clinical Developments." This review is available at our website, http://www.scimitarequity.com/. Scimitar Equity Research, Inc. provides independent, objective research and analysis of the health science industry for the institutional and investment communities. Scimitar does not own any securities or accept payment of fees in company stock related to the companies we provide analysis or develop research products. We do not have investment banking relationships with any company to maintain our independence and objectivity. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for continuing coverage and preparing this research review. This analysis and review does not have regard to the specific investment objectives, financial situation and the information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Please read all our important disclosures. CONTACT: Scimitar Equity Research, Inc. Henry W. McCusker Director of Research phone: (617) 236-6396 fax: (617) 236-6397 e-mail: DATASOURCE: Scimitar Equity Research, Inc. CONTACT: Henry W. McCusker, Director of Research of Scimitar Equity Research, Inc., +1-617-236-6396, Web site: http://www.scimitarequity.com/

Copyright